| Project/Area Number |
06670910
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
TONAMI Norihisa Kanazawa University, Dept.of Nucl.Med., Professor, 医学部, 教授 (60019940)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MICHIGISHI Takatoshi Kanazawa University, Dept.of Nucl.Med., Associate Professor, 医学部, 助教授 (60020012)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 1995: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1994: ¥500,000 (Direct Cost: ¥500,000)
|
|---|
| Keywords | T1-201 / malignant bone tumor / chemotherapy |
|---|
| Research Abstract |
The nude mouse model bearing human Ewing's sarcoma was used. T1-201 was injected intravenously and the counts in the blood and the tumor were measured sequentially.
T1-201 was rapidly taken up by the tumor and gradually decreased. While the radioactivity in the tumor was increased rapidly up to 10 min after injection and remained higher than that of blood afterward. Tumor uptake of T1-201 was significantly reduced in patients with effective chemotherapy with cis-diamminedichloroplatinum (II) as compared to the control group without treatment although the tumor volume was not affected by 12 days after cis-diamminedichloroplatinum (II) injection. The tumor uptake of T1-201 was proved to be a sensitive indicator for tumor cell activity.
Clinical study was performed by injection of T1-201 111MBq in 11 patients with malignant bone or soft tissue tumors before and after 3-5 courses of chemotherapy (cis-diamminedichloroplatinum (II), doxorubicin hydrochloride, caffeine. T1-201 uptake ratio of the tumor to normal tissue in the lesions with remarkable chemotherapeutic effect seems to be smaller compared to the lesions with inappreciable effect.
T1-201 scintigrapy seems to reflect chemotherapeutic effect for malignant bone or soft tissue tumors. We will report the final results after the evaluation of chemotherapeutic effect was derermined in all of cases.
|
